Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
Cerus Corp Chief Medical Officer Benjamin Richard reported multiple stock transactions in early March 2026. He received a grant or award of 55,220 shares of common stock on March 5, 2026, at no stated purchase price. Around the same time, he completed open-market sales totaling 125,894 shares at weighted average prices between about $1.88 and $2.06 per share, including block and multiple-price trades. A portion of the shares sold was under a pre-set Rule 10b5-1 instruction to cover tax withholding and related fees on vesting restricted stock units, described as non-discretionary. After these transactions, he directly owned 879,101 common shares.
Cerus Corp Chief Legal Officer Chrystal Jensen reported two stock transactions. On March 5, 2026, Jensen acquired 55,220 shares of common stock as a grant or award at $0.00 per share, bringing direct holdings to 1,083,514 shares. On March 6, 2026, Jensen sold 30,845 shares of common stock at a weighted average price of $2.0055 per share, leaving 1,059,139 shares directly owned. The sale was executed under a Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees related to vesting restricted stock units and was not a discretionary sale.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported both a stock grant and a tax-related sale of common shares. On March 5, 2026, he acquired 80,320 shares of common stock as a grant or award, increasing his direct holdings to 1,946,968 shares.
On March 6, 2026, he executed an open-market Rule 10b5-1 sale of 34,094 shares at a weighted average price of $2.0055 per share to cover statutory tax withholding obligations and related brokerage fees, a non-discretionary transaction that left him with 1,912,874 directly held shares.
CERUS CORP President and CEO William Mariner Greenman reported offsetting stock transactions. On March 5, 2026, he acquired 193,270 shares of common stock as a grant at $0.0000 per share. On March 6, 2026, he sold 78,187 shares at a weighted average price of $2.0055 per share pursuant to a Rule 10b5-1 instruction to cover statutory tax withholding and related brokerage fees. Following these transactions, he held 5,446,250 shares directly.
CERS insider sale filings reported by Richard J. Benjamin. The filing shows sales of 24,235 common shares on 03/06/2026 for $48,603.19 and 61,233 common shares on 03/05/2026 for $126,299.19. A broker-dealer listed is Morgan Stanley Smith Barney LLC with a reference date of 03/09/2026. The record also references 40,426 common shares tied to restricted stock dated 03/06/2025.
Morgan Stanley Smith Barney LLC notified a proposed sale of common stock for issuer-restricted shares related to CERS. The notice lists proposed sale activity tied to restricted stock grants dated 03/12/2023 (43,092 shares) and 03/12/2024 (12,133 shares), and references an aggregate number 192,171,776.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of restricted common stock of the issuer CERS (NASDAQ). The filing lists 52,385 restricted shares dated 03/12/2024 and 8,848 restricted shares dated 03/12/2022.
Cerus Corp’s chief medical officer, Benjamin Richard J, reported an equity grant on Form 4. On March 2, 2026, he acquired 264,000 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he directly holds 949,775 common shares. Each RSU converts into one share and vests in two installments: 34% on March 12, 2027 and 66% on March 12, 2028, subject to his continuous service with Cerus through each vesting date.
Green Kevin Dennis reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corporation’s Chief Financial Officer Kevin Dennis Green reported an award of 300,000 restricted stock units, each representing one share of common stock. The grant was at no cash cost to him and increases his direct holdings to 1,187,262 shares, including prior employee stock purchase plan shares.
The RSUs vest in two stages: 34% on March 12, 2027 and 66% on March 12, 2028, conditioned on his continued service with the company through each vesting date.
Cerus Corp reported that President and CEO William Mariner Greenman received a grant of 1,200,000 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest with 34% on March 12, 2027 and 66% on March 12, 2028, contingent on his continued service. Following this equity award and recent employee stock purchase plan acquisitions, his direct holdings total 5,331,167 shares of Cerus common stock.